Director, Center for Outcomes Research, Real World Evidence and Epidemiology
At Genmab, we are dedicated to building extraordinary futures by developing antibody products and groundbreaking oncology medicines that change lives and the future of cancer treatment. We strive to create, champion and maintain a global workplace where individual contributions are valued and drive innovative solutions to meet the needs of our patients, care partners, families and employees.
The Role
This position will be responsible for developing and executing HTA strategy in partnership with Market Access. This role requires strong scientific leadership, knowledge of HTA processes, cross‑functional influence, and external engagement experience with HTA agencies.
Responsibilities
* Drive the development, execution, and implementation of European evidence needs for HTA & post‑approval RWE for Genmab products across European markets of interest in alignment with market access and medical affairs.
* Co‑develop the JCA submission and HTA dossier with the Market Access and Pricing Lead to ensure the evidence on clinical and economic value of Genmab products is represented in a scientifically robust manner, consistent with evolving HTA standards.
* Provide input into global HEOR and RWE deliverables (e.g., economic model, global value dossier, global value evidence framework, ITC methods) regarding local country needs and lead validation of regional/local input.
* Lead evidence generation activities relevant to local markets, including localization of global deliverables and post‑approval evidence generation activities.
* Develop customer‑facing materials (e.g., field decks) to communicate value to access decision makers, champion the review through the MRL process and support training of customer‑facing teams as appropriate.
* Act as a scientific HEOR/RWE SME to market access in pricing and HTA negotiations.
* Contribute to department strategy and objectives and represent CORE on key initiatives.
* Support pipeline assets as needed.
Requirements
* Graduate (PhD or Masters) degree and relevant work experience in health economics, outcomes research, epidemiology, health services research, public health, or health policy.
* Minimum of 7 years in the pharmaceutical industry or consulting in the direct conduct of health economics, outcomes research, real‑world evidence, and epidemiology studies.
* Oncology experience preferred.
* Strong commercial and clinical strategic mindset.
* Demonstrated research accomplishments evidenced by a history of peer‑reviewed publications.
* Excellent knowledge of market access environment and HTA process in key European markets.
* Significant experience participating in HTA processes at country level in Germany, France or UK.
* Ability to work well in a team and cross‑functional environment, and to work independently with limited supervision.
* Ability to travel. Position can be filled in the UK, France, Germany, Italy or Spain.
* Ability to work successfully under pressure in a fast‑paced environment and with tight timelines.
* Ability to be proactive, enthusiastic, and goal‑oriented.
* Strong communication skills – both oral and written.
About You
* You are genuinely passionate about our purpose.
* You bring precision and excellence to all that you do.
* You believe in our rooted‑in‑science approach to problem‑solving.
* You are a generous collaborator who can work in teams with a broad spectrum of backgrounds.
* You take pride in enabling the best work of others on the team.
* You can grapple with the unknown and be innovative.
* You have experience working in a fast‑growing, dynamic company (or a strong desire to).
* You work hard and are not afraid to have a little fun while you do so.
Locations
The position can be filled in the UK, France, Germany, Italy, Spain, Netherlands or Denmark.
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its hard‑working, innovative and collaborative team has invented next‑generation antibody technology platforms and harnessed translational, quantitative and data sciences, resulting in a proprietary pipeline of bispecific T‑cell engagers, antibody‑drug conjugates, next‑generation immune checkpoint modulators and effector‑function‑enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock‑Your‑Socks‑Off (KYSO®) antibody medicines.
#J-18808-Ljbffr